In Q1 2026, Cumberland’s portfolio delivered net revenues of $9.1 million, while operating expenses reached $12.3 million, resulting in a net loss of $3.3 million and an adjusted loss of $1.9 million, or $0.13 per share. The balance sheet at March 31 showed $71.0 million in assets, $49.7 million in liabilities, and $21.6 million in shareholders’ equity.

Cumberland has agreed to sell its FDA-approved U.S. brands portfolio to Apotex for $100 million in cash, pending shareholder and regulatory approvals. The deal transfers branded commercial operations to Apotex and is intended to unlock value, enabling Cumberland to reallocate resources toward its development pipeline while maintaining majority ownership in Cumberland Emerging Technologies.

Cumberland’s lead development candidate, ifetroban, has achieved breakthrough Phase II results in Duchenne muscular dystrophy-associated cardiomyopathy and holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. Additional Phase II studies for systemic sclerosis and idiopathic pulmonary fibrosis are underway, with enrollment complete in the scleroderma trial and interim data pending in the IPF program.